Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 in adults with moderately to severely active ulcerative colitis
2020-000659-11Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GLPG3970 with Placebo (2 arms). Primary endpoint: Change from baseline in total Mayo Clinical Score at Week 6. Started Jul 2020; status: completed.
02
Drugs
GLPG3970
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-000659-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000659-11.